Webinar | On Demand Recording

World Preview 2024: Pharma’s Growth Boost – On Demand

Are you ready to look at the pharma landscape through a long-range lens? Evaluate has released new forecasts out to 2030. With obesity, immuno-inflammation and oncology driving an increase in CAGR to 2030 of 7.7%, the panel will discuss what this means for the 10 top-selling therapies and the domination of the so-called ‘big drugs for big diseases’.

Watch the webinar.

What to Expect

Novo and Lilly soar up the company charts, having just entered the top 10 last year.
Resurgent CNS and respiratory are both prominent among most valuable pipeline candidates.
The prescription drug market will hit $1.7 trillion.

Melanie Senior

Author, World Preview

Dan Chancellor

VP Norstella Thought Leadership

Paul Verdin

SVP, Consulting & Analytics, Evaluate